• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNA-9-5p 通过 AKT 信号通路下调 Klf4 并影响肝癌的进展。

MicroRNA‑9‑5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway.

机构信息

Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China.

The 5th Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200082, P.R. China.

出版信息

Int J Mol Med. 2019 Mar;43(3):1417-1429. doi: 10.3892/ijmm.2019.4062. Epub 2019 Jan 14.

DOI:10.3892/ijmm.2019.4062
PMID:30664155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6365078/
Abstract

Krüppel‑like factor 4 (Klf4) is a transcriptional factor involved in the progression of hepatocellular carcinoma (HCC). However, the underlying regulatory mechanisms associated with the Klf4 gene as a tumor suppressor in HCC remain unclear. microRNAs (miRNAs or miRs) are a series of small non‑coding RNAs that serve a vital role in regulating gene expression via their influence on protein translation and the associated degradation of mRNA. The mRNA expression levels of the miRNA, miR‑9‑5p, and Klf4 were measured using reverse transcription‑quantitative polymerase chain reaction. The protein expression levels of Klf4, protein kinase B (AKT), phosphorylated (p‑)AKT, mechanistic target of rapamycin (mTOR), p‑mTOR, B cell lymphoma‑2 (Bcl‑2) and Bcl‑2‑associated X protein (Bax) were determined by western blot analysis. Dual luciferase reporter assay was used to confirm a direct interaction between miR‑9‑5p and the 3'‑untranslated region (3'‑UTR) sequence of Klf4. Cell counting kit‑8 assay, wound healing assay, Transwell migration assay and flow cytometric analysis were performed to evaluate the proliferative, migratory and apoptotic capabilities of the HCC cells. In the present study, miR‑9‑5p was revealed to be overexpressed in HCC as a novel upstream gene of Klf4. miR‑9‑5p expression was inversely associated with Klf4 expression in clinical samples. Additionally, Kaplan‑Meier analysis revealed a markedly poor prognosis of HCC in the miR‑9‑5p high‑expression group. Bioinformatics analysis revealed that miR‑9‑5p bound directly to the 3'‑UTR of Klf4, which reduced the expression levels of Klf4. The miR‑9‑5p/Klf4 axis promoted HCC proliferation and migration, and inhibited HCC apoptosis. Furthermore, miR‑9‑5p upregulated the Bcl‑2/Bax protein ratio and activated AKT/mTOR signaling. Taken together, these data demonstrated that the miR‑9‑5p/Klf4 axis was able to promote HCC progression, which may occur via regulation of the AKT signaling pathway, highlighting a potential novel target in HCC treatment.

摘要

Krüppel 样因子 4(Klf4)是参与肝细胞癌(HCC)进展的转录因子。然而,Klf4 基因作为 HCC 肿瘤抑制因子的潜在调节机制尚不清楚。微小 RNA(miRNA 或 miR)是一系列小的非编码 RNA,通过影响蛋白质翻译和相关的 mRNA 降解,在调节基因表达方面发挥着重要作用。采用逆转录-定量聚合酶链反应测定 miRNA、miR-9-5p 和 Klf4 的 mRNA 表达水平。采用 Western blot 分析测定 Klf4、蛋白激酶 B(AKT)、磷酸化(p)AKT、雷帕霉素靶蛋白(mTOR)、p-mTOR、B 细胞淋巴瘤-2(Bcl-2)和 Bcl-2 相关 X 蛋白(Bax)的蛋白表达水平。双荧光素酶报告基因检测用于证实 miR-9-5p 与 Klf4 的 3'非翻译区(3'UTR)序列之间的直接相互作用。采用细胞计数试剂盒-8 检测、划痕愈合试验、Transwell 迁移试验和流式细胞术分析评估 HCC 细胞的增殖、迁移和凋亡能力。在本研究中,miR-9-5p 作为 Klf4 的新上游基因在 HCC 中呈现过度表达。miR-9-5p 的表达与临床样本中 Klf4 的表达呈负相关。此外,Kaplan-Meier 分析显示 miR-9-5p 高表达组 HCC 的预后明显较差。生物信息学分析显示,miR-9-5p 直接结合 Klf4 的 3'UTR,降低 Klf4 的表达水平。miR-9-5p/Klf4 轴促进 HCC 增殖和迁移,抑制 HCC 凋亡。此外,miR-9-5p 上调 Bcl-2/Bax 蛋白比值并激活 AKT/mTOR 信号通路。综上所述,这些数据表明,miR-9-5p/Klf4 轴能够促进 HCC 进展,可能通过调节 AKT 信号通路发生,提示 HCC 治疗的一个潜在新靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/e6b7f2c4d765/IJMM-43-03-1417-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/6971acc09870/IJMM-43-03-1417-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/cfa8d32c0337/IJMM-43-03-1417-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/fe5f063addc5/IJMM-43-03-1417-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/ecea25c178f3/IJMM-43-03-1417-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/e6b7f2c4d765/IJMM-43-03-1417-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/6971acc09870/IJMM-43-03-1417-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/cfa8d32c0337/IJMM-43-03-1417-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/fe5f063addc5/IJMM-43-03-1417-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/ecea25c178f3/IJMM-43-03-1417-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3c3/6365078/e6b7f2c4d765/IJMM-43-03-1417-g07.jpg

相似文献

1
MicroRNA‑9‑5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway.miRNA-9-5p 通过 AKT 信号通路下调 Klf4 并影响肝癌的进展。
Int J Mol Med. 2019 Mar;43(3):1417-1429. doi: 10.3892/ijmm.2019.4062. Epub 2019 Jan 14.
2
CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.CADM2 作为 miR-10b 的一个新靶点,通过 FAK/AKT 通路促进肝癌的肿瘤转移。
J Exp Clin Cancer Res. 2018 Mar 5;37(1):46. doi: 10.1186/s13046-018-0699-1.
3
miR‑145‑5p reduces proliferation and migration of hepatocellular carcinoma by targeting KLF5.miR-145-5p 通过靶向 KLF5 减少肝癌细胞的增殖和迁移。
Mol Med Rep. 2018 Jun;17(6):8332-8338. doi: 10.3892/mmr.2018.8880. Epub 2018 Apr 13.
4
MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma.微小 RNA-1468 通过激活 PPAR-γ 介导的 AKT 信号通路促进人肝癌的肿瘤进展。
J Exp Clin Cancer Res. 2018 Mar 6;37(1):49. doi: 10.1186/s13046-018-0717-3.
5
Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma.Klf4通过靶向人肝细胞癌中的微小RNA-31抑制肿瘤生长和转移。
Int J Mol Med. 2017 Jan;39(1):47-56. doi: 10.3892/ijmm.2016.2812. Epub 2016 Nov 24.
6
Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.微小RNA-16对肝癌细胞增殖、侵袭和转移的抑制作用。
Int J Mol Med. 2015 Dec;36(6):1713-9. doi: 10.3892/ijmm.2015.2379. Epub 2015 Oct 16.
7
SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma.SF3B4 受 microRNA-133b 调控,促进肝癌细胞增殖和转移。
EBioMedicine. 2018 Dec;38:57-68. doi: 10.1016/j.ebiom.2018.10.067. Epub 2018 Nov 1.
8
Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma.失调的 Krüppel 样因子 4 和维生素 D 受体信号通路促进肝细胞癌的进展。
Gastroenterology. 2012 Sep;143(3):799-810.e2. doi: 10.1053/j.gastro.2012.05.043. Epub 2012 Jun 4.
9
SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.SPAG5 通过 PI3K/AKT 通路与 CEP55 相互作用,在肝癌中发挥致癌活性。
Mol Cancer. 2018 Aug 8;17(1):117. doi: 10.1186/s12943-018-0872-3.
10
MicroRNA-493 suppresses cell proliferation and invasion by targeting ZFX in human hepatocellular carcinoma.微小 RNA-493 通过靶向 ZFX 抑制人肝癌细胞的增殖和侵袭。
Cancer Biomark. 2018;22(3):427-434. doi: 10.3233/CBM-171036.

引用本文的文献

1
Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma.Krüppel样因子信号通路改变与肝细胞癌的潜在靶向治疗
Anticancer Agents Med Chem. 2025;25(2):75-85. doi: 10.2174/0118715206301453240910044913.
2
MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.微小 RNA 与肝细胞癌发病机制:对机制和治疗机会的深入了解。
Int J Mol Sci. 2024 Aug 29;25(17):9393. doi: 10.3390/ijms25179393.
3
MicroRNA-mediated Krüppel-like factor 4 upregulation induces alternatively activated macrophage-associated marker and chemokine transcription in 4,4'-methylene diphenyl diisocyanate exposed macrophages.

本文引用的文献

1
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.以小分子抑制剂 AUY922(luminespib)靶向 HSP90 作为治疗肝细胞癌的策略。
Int J Cancer. 2019 May 15;144(10):2613-2624. doi: 10.1002/ijc.31963. Epub 2018 Dec 24.
2
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.肝细胞癌的全身治疗:最新进展
Cancers (Basel). 2018 Oct 30;10(11):412. doi: 10.3390/cancers10110412.
3
Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
微小 RNA 介导的 Krüppel 样因子 4 上调诱导 4,4'-亚甲基二苯基二异氰酸酯暴露的巨噬细胞中交替激活的巨噬细胞相关标志物和趋化因子转录。
Xenobiotica. 2024 Sep;54(9):730-748. doi: 10.1080/00498254.2024.2334329. Epub 2024 Apr 19.
4
Therapeutic Targeting of Krüppel-Like Factor 4 and Its Pharmacological Potential in Parkinson's Disease: a Comprehensive Review.Krüppel 样因子 4 的治疗靶点及其在帕金森病中的药理作用:全面综述。
Mol Neurobiol. 2024 Jun;61(6):3596-3606. doi: 10.1007/s12035-023-03800-2. Epub 2023 Nov 24.
5
inhibits the growth and metastasis of liver cancer by downregulating miR-9-5p and upregulating PDK4.通过下调 miR-9-5p 和上调 PDK4 抑制肝癌的生长和转移。
Cancer Biol Ther. 2023 Dec 31;24(1):2246198. doi: 10.1080/15384047.2023.2246198. Epub 2023 Sep 29.
6
Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis.去泛素化酶 YOD1 调节 CDK1 的稳定性并驱动三阴性乳腺癌的肿瘤发生。
J Exp Clin Cancer Res. 2023 Sep 4;42(1):228. doi: 10.1186/s13046-023-02781-3.
7
miR-9-5p expression is associated with vascular invasion and prognosis in hepatocellular carcinoma, and in vitro verification.miR-9-5p 的表达与肝癌的血管侵犯和预后相关,并进行了体外验证。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14657-14671. doi: 10.1007/s00432-023-05257-1. Epub 2023 Aug 16.
8
A miR-9-5p/FOXO1/CPEB3 Feed-Forward Loop Drives the Progression of Hepatocellular Carcinoma.miR-9-5p/FOXO1/CPEB3 正反馈环路驱动肝细胞癌的进展。
Cells. 2022 Jul 5;11(13):2116. doi: 10.3390/cells11132116.
9
hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration.hsa-miR-9-5p 介导的 TSPAN9 下调与肝细胞癌不良预后和肿瘤免疫浸润呈正相关。
J Immunol Res. 2022 May 12;2022:9051229. doi: 10.1155/2022/9051229. eCollection 2022.
10
Identification and Characterization of MicroRNAs Involving in Initial Sex Differentiation of Gonads.参与性腺初始性别分化的微小RNA的鉴定与特征分析
Biology (Basel). 2022 Mar 16;11(3):456. doi: 10.3390/biology11030456.
肝胆肿瘤的生物标志物驱动和分子靶向治疗。
Semin Oncol. 2018 Jun;45(3):116-123. doi: 10.1053/j.seminoncol.2018.03.002. Epub 2018 Mar 16.
4
Targeting of G-Quadruplex Harboring Pre-miRNA 92b by LNA Rescues PTEN Expression in NSCL Cancer Cells.靶向含有 miRNA 92b 的 G-四链体通过 LNA 恢复 NSCLC 细胞中的 PTEN 表达。
ACS Chem Biol. 2018 Apr 20;13(4):909-914. doi: 10.1021/acschembio.7b00749. Epub 2018 Mar 19.
5
Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages.手术切除可提高不同巴塞罗那临床肝癌分期的肝细胞癌患者的长期生存率。
Cancer Manag Res. 2018 Feb 21;10:361-369. doi: 10.2147/CMAR.S152707. eCollection 2018.
6
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
7
Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis.对美国癌症联合委员会(AJCC)第8版肝细胞癌(HCC)患者分期系统的批判性评估:一项监测、流行病学与最终结果(SEER)分析。
J Surg Oncol. 2018 Mar;117(4):644-650. doi: 10.1002/jso.24908. Epub 2017 Nov 11.
8
Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression.环状 RNA circMTO1 作为 microRNA-9 的海绵体抑制肝癌进展。
Hepatology. 2017 Oct;66(4):1151-1164. doi: 10.1002/hep.29270. Epub 2017 Aug 26.
9
Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.非编码 RNA 在肝细胞癌中的作用:机制、生物标志物和治疗靶点。
J Hepatol. 2017 Sep;67(3):603-618. doi: 10.1016/j.jhep.2017.04.009. Epub 2017 Apr 22.
10
SP and KLF Transcription Factors in Digestive Physiology and Diseases.消化生理学与疾病中的速激肽和Krüppel样因子转录因子
Gastroenterology. 2017 Jun;152(8):1845-1875. doi: 10.1053/j.gastro.2017.03.035. Epub 2017 Mar 30.